From: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
CL(L/day) | Kout (day-1) | V1(L) | V2(L) | ||
---|---|---|---|---|---|
n | p | ||||
Age | 44 | 0.86 | 0.82 | 0.90 | 0.99 |
Sex male versus female | 23 versus 21 | 0.59 | 0.53 | 0.34 | 0.37 |
Body surface area (BSA, m2) | 44 | 0.59 | 0.82 | 0.76 | 0.99 |
Binet stage A or B versus C | 27 versus 17 | 0.89 | 0.82 | 0.34 | 0.99 |
Treatment RB versus RFC | 17 versus 28 | 0.48 | 0.82 | 0.76 | 0.99 |
Lymphocytosis | 44 | 0.59 | 0.30 | 0.96 | 0.99 |
Areas of lymphadenopathy | 44 | 0.59 | 0.39 | 0.96 | 0.51 |
CD38 positivity (≥30%) versus negativity | 21 versus 22 | 0.88 | 0.82 | 0.90 | 0.99 |
FCGR F/F versus V/F and V/V | 25 versus 19 | 0.86 | 0.68 | 0.90 | 0.99 |
IGHV unmutated versus mutated status | 10 versus 6 | 0.37 | 0.82 | 0.96 | 0.99 |
Cytogenetics | |||||
Isolated del(13q) versus others | 8 versus 36 | 0.37 | 0.02 | 0.76 | 0.23 |
Trisomy 12 versus others | 10 versus 34 | 0.59 | 0.92 | 0.76 | 0.37 |
Normal caryotype versus others | 4 versus 40 | 0.89 | 0.39 | 0.96 | 0.66 |
Del(11q) versus others | 10 versus 34 | 0.37 | 0.17 | 0.76 | 0.17 |
Del(17p) versus others | 9 versus 35 | 0.17 | 0.007 | 0.17 | 0.23 |
Time to relapse (TTR) | 44 | 0.59 | 0.82 | 0.96 | 0.99 |
Time to second treatment (TST) | 44 | 0.37 | 0.39 | 0.96 | 0.99 |